The Blood Brain Barrier Technologies Market To Witness An Effervescence Of Growth In The Next Decade

Blood Brain Barrier Technologies Market

The healthcare industry is witnessing unprecedented bonding across organizations, governments, and academia and undoubtedly demonstrating the value of being in sync with innovations and enhanced outcomes. In other words, the Blood Brain Barrier Technologies Market will witness the assimilation of datasets and interventions for saving on costs and improving users’ experience.

Brain is one of the largest and most complex organs in the human body. It comprises 100 billion nerves that communicate with a 100 trillion synapses. It is made up of hindbrain, midbrain, and forebrain. It is responsible for thought and movement produced by the body. The brain has its own security system-a filtering mechanism comprising blood vessels that allow entry of essential nutrients while blocking other substances-known as the blood-brain barrier.

Blood-brain barrier is a semi permeable dynamic interface that separates the capillaries that carry blood to the brain and spinal cord tissue by blocking the passage of certain substances. It is formed by highly specialized endothelial cells. The vessels of the blood-brain barrier are composed of specialized endothelial cell that line brain capillaries from the vascular system that lack fenestration of pores and allow rapid exchange of molecules between vessels and tissues.

Get Sample Copy of this Report @

The blood-brain barrier protects the neural tissue from harmful chemicals and maintains a stable environment. Unfortunately, this barrier is so effective at blocking the passage of foreign substances that it often prevents penetration of life-saving drugs to address issues such as injuries and diseases. Thus, discovery of new modalities allowing the effective delivery of drugs and bio-macromolecules to the central nervous system (CNS) is of great importance for the treatment of neurodegenerative disorders. Neurodegeneration and neuroinflammation are key events in CNS disorders like stroke, Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis.

However, the drugs for CNS treatment, such as neurotrophic factors, including BDNF, EPO (erythropoietin), and anti-inflammatory antibodies (e.g., Enbrel and Remicade), do not cross the blood-brain barrier in effective therapeutic quantities.

Request for Table of Content @

North America dominates the global market for blood-brain barrier technologies given the rising incidence of neurological diseases and growing geriatric population in the region. Asia is expected to show high growth rates in the next five years in the global blood-brain barrier technologies market, with China and India being the fastest growing markets in Asia Pacific. The key driving forces for the blood-brain barrier technologies market in developing countries are the large pool of patients, increasing awareness about the disease, improving healthcare infrastructure, and rising government funding in the region.

Increasing prevalence of neurological diseases such as meningitis, multiple sclerosis, Parkinson’s disease, and encephalitis, growing geriatric population, increasing in healthcare expenditure, rising investment in research and development for the development of new drugs and delivery devices, increasing awareness about healthcare, and increasing number of initiatives by various governments and government associations are some of the key factors driving the growth of the global blood-brain barrier technologies market.

Access Full Report @

However, complex regulatory frameworks for the approval of drugs in most countries and long approval time for drugs owing to the insufficient knowledge of the brain are major restraints for the growth of the global blood-brain barrier technologies market.

Innovation of drugs and delivery devices to cross the blood-brain barrier would help develop opportunities for the global blood-brain barrier technologies market. The major companies operating in the global blood-brain barrier technologies market are Teva Pharmaceuticals Industries, Ltd., F. Hoffmann La-Roche, Ltd., Eli Lilly and Company, Fabre-Kramer Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., biOasia Technologies, Inc., Cypress Biosciences, Inc., Janssen Pharmaceutical N.V., NeuroVive Pharmaceutical AB, and ArmaGen.

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.

Contact Us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales –
Website –

Back to top button